Equities research analysts forecast that Heska Corp (NASDAQ:HSKA) will announce sales of $31.65 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heska’s earnings. The highest sales estimate is $31.67 million and the lowest is $31.63 million. Heska reported sales of $30.38 million in the same quarter last year, which suggests a positive year over year growth rate of 4.2%. The business is scheduled to report its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Heska will report full year sales of $31.65 million for the current fiscal year, with estimates ranging from $138.30 million to $138.90 million. For the next financial year, analysts anticipate that the company will report sales of $152.44 million per share, with estimates ranging from $150.54 million to $156.19 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Heska.
Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported $0.63 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.07. Heska had a net margin of 7.53% and a return on equity of 16.23%. The firm had revenue of $36.04 million for the quarter, compared to the consensus estimate of $40.56 million. During the same quarter in the previous year, the company earned $0.46 earnings per share. The business’s revenue was down 8.8% compared to the same quarter last year.
Several large investors have recently modified their holdings of HSKA. BNP Paribas Arbitrage SA boosted its stake in shares of Heska by 74.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 3,248 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 1,390 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its stake in shares of Heska by 58.9% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 2,400 shares of the medical research company’s stock valued at $211,000 after purchasing an additional 890 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Heska by 3.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 100,278 shares of the medical research company’s stock valued at $8,834,000 after purchasing an additional 3,610 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Heska in the 3rd quarter valued at $108,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Heska by 10.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 48,209 shares of the medical research company’s stock valued at $4,247,000 after purchasing an additional 4,691 shares in the last quarter. Institutional investors own 85.21% of the company’s stock.
HSKA traded down $0.74 during trading on Tuesday, reaching $74.18. 28,454 shares of the company’s stock were exchanged, compared to its average volume of 103,201. Heska has a fifty-two week low of $56.59 and a fifty-two week high of $115.00. The company has a market capitalization of $565.46, a P/E ratio of 36.60, a P/E/G ratio of 2.11 and a beta of 0.65.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3335576/31-65-million-in-sales-expected-for-heska-corp-hska-this-quarter.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.